The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

EXCLUSIVE: After successfully relaunching the Bad Boys franchise, Sony Pictures looks to be ready to dust off its black suit and shades as a new Men In Black film is now in development. Sources tell ...

And now more cities are implementing curbside composting to help them meet their sustainability goals. New York is currently rolling out a mandatory composting program that will soon be effect in ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

At Ford Field on Thursday, Amon-Ra St. Brown and the Detroit Lions (7-5) face Javonte Williams and the Dallas Cowboys (6-5-1) in a matchup featuring two of the brightest stars in the NFL, beginning at ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Choncé is a personal finance freelance writer who enjoys writing about credit cards, business loans, debt management, and helping people achieve financial wellness. Having a background in journalism, ...